Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH – Get Free Report) major shareholder Paul Vigano sold 14,500,002 shares of Aveanna Healthcare stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $11.50, for a total transaction of $166,750,023.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Aveanna Healthcare Stock Up 4.1%
Shares of Aveanna Healthcare stock traded up $0.54 during midday trading on Monday, hitting $13.70. The company had a trading volume of 5,371,630 shares, compared to its average volume of 1,804,159. The company has a debt-to-equity ratio of 4.47, a quick ratio of 1.16 and a current ratio of 1.16. The stock has a market capitalization of $2.99 billion, a P/E ratio of 11.14, a P/E/G ratio of 0.92 and a beta of 1.90. The company has a 50 day moving average of $9.58 and a 200 day moving average of $7.92. Aveanna Healthcare Holdings Inc. has a 52-week low of $5.93 and a 52-week high of $13.98.
Aveanna Healthcare (NASDAQ:AVAH – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.17 by $0.05. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%.The company had revenue of $670.48 million during the quarter, compared to analyst estimates of $638.61 million. On average, equities analysts predict that Aveanna Healthcare Holdings Inc. will post 0.68 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Aveanna Healthcare
Aveanna Healthcare News Summary
Here are the key news stories impacting Aveanna Healthcare this week:
- Positive Sentiment: Royal Bank of Canada raised its price target for Aveanna Healthcare from $10 to $16 and upgraded the stock to “outperform.” The new target implies additional upside from recent trading levels, providing a bullish signal for AVAH. Benzinga analyst price-target report
- Neutral Sentiment: Truist Financial increased its price target from $11 to $15 but maintained a “hold” rating. The higher valuation suggests improved expectations, while the unchanged rating indicates the firm does not see a compelling reason to become more bullish after the stock’s recent advance. Benzinga analyst price-target report
- Negative Sentiment: Several insiders sold a combined 320,000 shares at an average price of $11.50, generating approximately $3.68 million. CEO Jeff Shaner sold 90,000 shares, director Rodney D. Windley sold 180,000, and insider Edwin C. Reisz sold 50,000. Each retained a substantial stake, but the coordinated sales—particularly Windley’s roughly 8% position reduction—could raise concerns about insider confidence or add near-term selling pressure. CEO insider sale filing Director insider sale filing Insider sale filing
Wall Street Analysts Forecast Growth
A number of equities analysts recently issued reports on the stock. Barclays upped their price target on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a research note on Thursday, July 9th. Wall Street Zen cut shares of Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 15th. BMO Capital Markets upped their target price on shares of Aveanna Healthcare from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Royal Bank Of Canada raised their price target on shares of Aveanna Healthcare from $10.00 to $16.00 and gave the company an “outperform” rating in a research report on Monday. Finally, Stephens upgraded shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $10.00 to $11.00 in a report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, Aveanna Healthcare has a consensus rating of “Moderate Buy” and a consensus target price of $12.89.
Check Out Our Latest Stock Analysis on Aveanna Healthcare
About Aveanna Healthcare
Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.
In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.
Recommended Stories
- Five stocks we like better than Aveanna Healthcare
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Aveanna Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aveanna Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
